3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
21
Leukemia
9
Gastrointestinal Stromal Tumors
4
Philadelphia Chromosome
3
Leukemia, Myeloid, Chronic-Phase
3
Leukemia, Myeloid
3
Bone Marrow Diseases
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms
2
Myeloproliferative Disorders
2
Hematologic Neoplasms
2
Bronchiolitis Obliterans Syndrome
2
Sarcoma
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
Hematologic Diseases
1
Interventions
ponatinib
2
napabucasin
2
Irinotecan
2
Imatinib Mesylate
2
Gemcitabine
2
130-nm albumin-bound paclitaxel
2
pralsetinib
1
pembrolizumab
1
nilotinib
1
linifanib
1
ibritumomab tiuxetan
1
bosutinib
1
Vorinostat
1
Temozolomide
1
Sorafenib
1
Rituximab
1
Pemetrexed
1
Paclitaxel
1
Melphalan
1
Leucovorin
1
Fluorouracil
1
FANG vaccine
1
Etoposide
1
Cytarabine
1
Cisplatin
1
Carmustine
1
Carboplatin
1
Bortezomib
1
Bevacizumab
1
BID protein, human
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasms by Histologic Type
×
nilotinib
×
Clear all
NCT02627677
2021-11-26
OPTIC-2L
Takeda
Phase 3
Terminated
44 enrolled
22 charts